Authors

Dennis Cooper, MD

Latest:

Dr. Cooper on Leveraging Novel Agents and Combos in Multiple Myeloma

Dennis Cooper, MD, sheds light on the novel therapeutic regimens available to patients with multiple myeloma.

Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center

Latest:

The Investigational Pipeline for Advanced BTC

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Sundar Jagannath, MBBS

Latest:

Dr Jagannath on the Potential Utility of Linvoseltamab in R/R Multiple Myeloma

Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Ashutosh K. Tewari, MD

Latest:

Dr. Tewari on the Factors to Consider for Robotic Radical Prostatectomy in Prostate Cancer

Ashutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy for a patient with prostate cancer.

Heather Simonsen, MA

Latest:

Media Training Helps Investigators, Institutions Shine

Here are 5 tips and tricks to help you shine when the spotlight is on you.

Albiruni Ryan Abdul Razak, MRCP, MBBCh

Latest:

Dr. Abdul Razak on Initial Findings With Durvalumab Plus Olaparib or Cediranib in Leiomyosarcoma

Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.

Rachel E. Factor, MD, MS

Latest:

Dr. Factor on the Lack of Standardization in Biomarker Testing in Breast and GI Cancers

Rachel E. Factor, MD, MS, discusses the lack of standardization with biomarker testing in breast and gastrointestinal cancers.

Andreana N. Holowatyj, PhD, MSCI

Latest:

Dr Holowatyj on the Potential Role of Germline Genetic Features in Appendiceal Cancer Susceptibility

Andreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.

Elan Diamond, MD

Latest:

Cabozantinib + Nivolumab Regimen in the Treatment of Advanced RCC

A discussion on the role of the cabozantinib and nivolumab regimen in the treatment of advanced RCC.

John Allan, MD, Weill Cornell Medicine

Latest:

Dr Allan on the Importance of BTK Inhibitors and BCL2 Inhibitors in CLL

John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.

Sheena Bhalla, MD

Latest:

Dr. Bhalla on Unmet Needs in the Treatment of EGFR Exon 20–Mutant NSCLC

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

Suzanne Lentzsch, MD, PhD, Columbia University

Latest:

Dr Lentzsch on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Suzanne Lentzsch, MD, PhD, discusses the safety profile of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Satya Das, MD, MSCI

Latest:

Dr. Das on the Results of a Clinical Score Analysis in Patients With NETs

Satya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.

Martin Wermke, MD

Latest:

Dr Wermke on the Investigation of BI 764532 in DLL3+ SCLC and NEC

Martin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Filippo de Marinis, MD

Latest:

Dr. de Marinis on the PERLA Trial in Metastatic NSCLC

Filippo de Marinis, MD, discusses the goal of the phase 2 PERLA trial in metastatic nonsquamous non–small cell lung cancer, as well as significant results from a primary analysis of this study.

Oncology Live® Staff

Latest:

Superagonists Pull IL-15 Into Focus in Oncology Care

Following in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.

Alice Bertaina MD, PhD

Latest:

Dr Bertaina on T-allo10 Infusion in Young Patients With Hematologic Malignancies

Alice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.

Ruchi Garg, MD

Latest:

Women in Oncology: Lessons to Tell Up-and-Coming Female Oncologists

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

Mark A. Lewis, MD

Latest:

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Adana A.M. Llanos, PhD, MPH

Latest:

Dr Llanos on Prediagnositic Allostatic Load and Breast Cancer Clinicopathology in Black Women

Adana A.M. Llanos, PhD, MPH, discusses the relationship between prediagnostic allostatic load and breast cancer clinicopathology in Black women.